AI Integration Across the Lifecycle (2026 Status)

Artificial intelligence is now deployed at every stage of the drug safety lifecycle, from molecular toxicity prediction in the laboratory to agentic case processing in post-marketing operations. Regulators are progressively adopting and codifying the Human-in-the-Loop model for AI across the safety lifecycle. The CIOMS WG XIV final report (December 2025), FDA-EMA joint principles (January 2026), and EMA GVP Module IX Rev 2 (2025) all establish the same baseline: AI can assist, automate, and augment — but qualified human oversight remains the final authority for every safety decision with regulatory or patient-safety consequences.

The through-line across every row in this table is the same: AI compresses the time between raw data and a structured, actionable output — but never removes the human checkpoint at the point where clinical judgment matters. A 40–65% cycle-time reduction in case processing sounds dramatic, and it is, but it describes how fast a case reaches a qualified human reviewer, not a replacement for that reviewer.